An analysis of 86 women who were HER-2 positive, had locally advanced breast cancer or metastatic breast cancer (MBC), and developed resistance to trastuzumab, demonstrated that the trastuzumab combined with capecitabine led to a not significantly inferior PFS compared with lapatinib, with a median PFS (7.1 months on LX vs 6.1 months on HX, HR 0.81, 90% CI 0.55–1.21, P = 0.39 )[24]. The gene discussed is ERBB2; the disease is breast cancer.